NKG2D/CLDN18.2 CAR-T(KD-496) in the Treatment of Advanced NKG2DL+/CLDN18.2+ Solid Tumors

Phase 0 Unknown 18 enrolled jianming xu KAEDI · collab

NaSingle-groupOpen-labelTreatment

Summary

This is a Phase 1, single-arm, single-center, open-label study to evaluate the safety and effectiveness of NKG2D/CLDN18.2-based CAR-T cells infusion in the treatment of advanced NKG2DL+/CLDN18.2+ solid tumors.

Timeline

Start: 2022-10-13
Primary completion: 2024-06-01
Completion: 2026-06-01

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	KD-496	Cell therapy	—	—

NKG2D/CLDN18.2 CAR-T(KD-496) in the Treatment of Advanced NKG2DL+/CLDN18.2+ Solid Tumors

Summary

Timeline

Drugs

Indications